Canaccord initiated coverage of Establishment Labs (ESTA) with a Buy rating and $60 price target The company’s portfolio is positioned to win considerable share in the U.S. market as its launch continues and it submits more indications to the FDA, the analyst tells investors in a research note. The firm says Establishment is seeking expand its total addressable market to patients who were previously unlikely to undergo breast augmentations with the launch of its smaller implant, minimally invasive procedure named Mia.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs Reports Strong Growth Amid Challenges
- Establishment Labs Reports Strong Q2 2025 Revenue Growth
- Establishment Labs Holdings: Strong Financial Performance and Promising Market Trends Justify Buy Rating
- Establishment Labs reports Q2 EPS (57c), consensus (56c)
- Strong Future Performance Anticipated for Establishment Labs Holdings: Buy Rating Affirmed